AU2006230447A1 - Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors - Google Patents

Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors Download PDF

Info

Publication number
AU2006230447A1
AU2006230447A1 AU2006230447A AU2006230447A AU2006230447A1 AU 2006230447 A1 AU2006230447 A1 AU 2006230447A1 AU 2006230447 A AU2006230447 A AU 2006230447A AU 2006230447 A AU2006230447 A AU 2006230447A AU 2006230447 A1 AU2006230447 A1 AU 2006230447A1
Authority
AU
Australia
Prior art keywords
dimethyl
ome
group
compound
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006230447A
Other languages
English (en)
Inventor
Marco A. Biamonte
Marcus F. Boehm
Srinivas R. Kasibhatla
Jiandong Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conforma Therapeutics Corp
Original Assignee
Conforma Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37054161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006230447(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conforma Therapeutics Corp filed Critical Conforma Therapeutics Corp
Publication of AU2006230447A1 publication Critical patent/AU2006230447A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
AU2006230447A 2005-03-30 2006-03-29 Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors Abandoned AU2006230447A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66689905P 2005-03-30 2005-03-30
US60/666,899 2005-03-30
PCT/US2006/011846 WO2006105372A2 (en) 2005-03-30 2006-03-29 Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors

Publications (1)

Publication Number Publication Date
AU2006230447A1 true AU2006230447A1 (en) 2006-10-05

Family

ID=37054161

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006230447A Abandoned AU2006230447A1 (en) 2005-03-30 2006-03-29 Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors

Country Status (15)

Country Link
US (2) US7544672B2 (US07544672-20090609-C00045.png)
EP (1) EP1869027A4 (US07544672-20090609-C00045.png)
JP (1) JP2008534609A (US07544672-20090609-C00045.png)
KR (1) KR20080004550A (US07544672-20090609-C00045.png)
CN (1) CN101180297A (US07544672-20090609-C00045.png)
AU (1) AU2006230447A1 (US07544672-20090609-C00045.png)
BR (1) BRPI0609509A2 (US07544672-20090609-C00045.png)
CA (1) CA2602257A1 (US07544672-20090609-C00045.png)
EA (1) EA013522B1 (US07544672-20090609-C00045.png)
IL (1) IL186270A (US07544672-20090609-C00045.png)
MX (1) MX2007011903A (US07544672-20090609-C00045.png)
NO (1) NO20075099L (US07544672-20090609-C00045.png)
NZ (1) NZ561939A (US07544672-20090609-C00045.png)
WO (1) WO2006105372A2 (US07544672-20090609-C00045.png)
ZA (1) ZA200708520B (US07544672-20090609-C00045.png)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609509A2 (pt) * 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
BRPI0708779A2 (pt) * 2006-03-11 2011-06-14 Vernalis R & D derivados de pirrolopirimidina utilizados como inibidores de hsp90
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
CN101490052B (zh) 2006-05-12 2012-08-08 美瑞德生物工程公司 治疗性化合物及其在癌症中的用途
WO2008045529A1 (en) * 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
WO2008093075A2 (en) 2007-02-01 2008-08-07 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
JP4523073B2 (ja) * 2007-02-06 2010-08-11 ファイザー・インク 癌を治療するためのＨＳＰ−９０阻害剤としての２−アミノ−５，７−ジヒドロ−６Ｈ−ピロロ［３，４−ｄ］ピリミジン誘導体
WO2009030871A1 (en) * 2007-09-07 2009-03-12 Vernalis R & D Ltd Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
CA2732922A1 (en) 2008-08-13 2010-02-18 Pfizer Inc. 2-amino pyrimidine compounds as potent hsp-90 inhibitors
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
GB0819105D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
GB0819102D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
EP2493571B1 (en) * 2009-10-29 2014-07-23 Janssen Pharmaceutica NV Alkynyl derivatives useful as dpp-1 inhibitors
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
WO2015153496A1 (en) * 2014-03-30 2015-10-08 Cepheid Modified thymine polynucleotide oligomers and methods
CN106460058B (zh) * 2014-03-30 2019-07-09 赛沛 经修饰的胞嘧啶多核苷酸寡聚物和方法
KR102133569B1 (ko) * 2018-06-28 2020-07-13 한국과학기술연구원 신규한 피롤로[2,3-d]피리미딘-4-온 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CN115192712B (zh) * 2022-07-05 2023-08-01 四川大学华西第二医院 Hsp抑制剂在制备胚胎神经系统畸形治疗的产品中的应用

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3595955A (en) 1969-03-26 1971-07-27 Upjohn Co Geldanamycin and process for producing same
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
IL64501A (en) 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4806642A (en) 1984-10-05 1989-02-21 Warner-Lambert Company Purine derivatives
US4921859A (en) 1983-10-31 1990-05-01 Warner-Lambert Company Purine derivatives
US5098906A (en) 1983-10-31 1992-03-24 Warner-Lambert Company Purine derivatives
US4547573A (en) 1983-12-02 1985-10-15 Ici Pharma Process for preparing cephalosporin derivatives
DE3578499D1 (de) 1984-02-02 1990-08-09 Merck & Co Inc 5-(amino oder substituiertes amino)-1,2,3-triazole.
US4748177A (en) 1984-03-26 1988-05-31 Warner-Lambert Company Guanine derivatives
US4617304A (en) 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
IT1196261B (it) 1984-09-20 1988-11-16 Pierrel Spa Derivati nucleosidici e purinici 8-sostituiti
US4772606A (en) 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
IL76546A (en) 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
JO1406B1 (en) 1984-11-02 1986-11-30 سميث كلاين اند فرينش لابوراتوريز ليمتد Chemical compounds
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
DE3512194A1 (de) 1985-04-03 1986-10-09 Hoechst Ag, 6230 Frankfurt Ein neues ansamycin-antibiotikum, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel
GB8515934D0 (en) 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US4918162A (en) 1986-05-06 1990-04-17 The Regents Of The University Of California Assays and antibodies for N-MYC proteins
US5002950A (en) 1986-10-24 1991-03-26 Warner-Lambert Co. 7-deazaguanines as immunomodulators
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5204353A (en) 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
SE8801729D0 (sv) 1988-05-06 1988-05-06 Astra Ab Purine derivatives for use in therapy
US4923885A (en) 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
EP0363320A3 (de) 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
ES2085446T3 (es) 1990-07-04 1996-06-01 Merrell Pharma Inc Derivados de acido 9-purinil fosfonico.
GB9020931D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
ES2139588T3 (es) 1991-03-05 2000-02-16 Ajinomoto Kk Derivado de ciclopropano.
WO1992021032A1 (en) 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
US6025126A (en) 1991-10-28 2000-02-15 Arch Development Corporation Methods and compositions for the detection of chromosomal aberrations
CA2127457A1 (en) 1992-01-06 1993-07-22 Walter P. Cullen Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone
CA2093403C (en) 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
JPH0680670A (ja) 1992-09-03 1994-03-22 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
US6005107A (en) 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
GB9226879D0 (en) 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5744492A (en) 1993-09-17 1998-04-28 United States Of America Method for inhibiting angiogenesis
US5602156A (en) 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
JP3769737B2 (ja) 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5994361A (en) 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH0841035A (ja) 1994-08-05 1996-02-13 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
US5846749A (en) 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
JPH08208687A (ja) 1994-11-25 1996-08-13 Sankyo Co Ltd グリセリルオリゴヌクレオチド
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
JPH0920776A (ja) 1995-06-30 1997-01-21 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法及びその誘導体を有効成分とする抗ウイルス剤
JPH09169758A (ja) 1995-10-18 1997-06-30 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法、及びそれを用いた抗ウイルス剤
JPH1025294A (ja) 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
ATE283855T1 (de) 1996-07-03 2004-12-15 Sumitomo Pharma Neue purinderivate
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US5861503A (en) 1997-04-30 1999-01-19 The Regents Of The University Of California Process for producing 8-fluoropurines
JP4903922B2 (ja) 1997-05-14 2012-03-28 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 選択された蛋白質を分解する複合化合物
PL337888A1 (en) 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
WO1999016465A1 (en) 1997-09-30 1999-04-08 Beth Israel Deaconess Medical Center Method for inhibiting tumor angiogenesis in a living subject
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
KR100540046B1 (ko) 1997-11-12 2006-01-10 미쓰비시 가가꾸 가부시키가이샤 퓨린유도체 및 이를 유효성분으로 함유하는 의약
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
AU3378599A (en) 1998-04-03 1999-10-25 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
SI20022A (sl) 1998-07-29 2000-02-29 Kemijski inštitut Alkilno substituirani purinovi derivati in njihova priprava
JP2000072773A (ja) 1998-08-28 2000-03-07 Zeria Pharmaceut Co Ltd プリン誘導体
JP2000072733A (ja) 1998-08-31 2000-03-07 Kanebo Ltd アミド化合物の製造法
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
WO2000037050A1 (en) 1998-12-22 2000-06-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-insoluble drug delivery system
DE60042731D1 (de) 1999-01-06 2009-09-24 Univ Southern California Methode und zubereitung zur hemmung von angiogenese
KR20010093308A (ko) 1999-02-01 2001-10-27 씨브이 쎄러퓨틱스, 인코포레이티드 사이클린 의존성 키나제 2 및 Ｉκ-Ａα의 퓨린 억제제
FR2790702B1 (fr) 1999-03-08 2001-07-20 Sidel Sa Unite de moulage et machine d'extrusion-soufflage munie d'une telle unite
US6174875B1 (en) 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
EP1169319A4 (en) 1999-04-09 2005-02-09 Sloan Kettering Institutefor C METHODS AND COMPOSITIONS FOR DEGRADING AND / OR INHIBITING TYROSINE KINASES BELONGING TO THE HER FAMILY
WO2000068230A1 (en) 1999-05-05 2000-11-16 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
JP2005519848A (ja) * 2000-11-02 2005-07-07 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０に結合するための小分子組成物
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
MY141789A (en) 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
US20020156277A1 (en) 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
US20030022864A1 (en) 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
JP2003113181A (ja) 2001-10-04 2003-04-18 Sumika Fine Chemicals Co Ltd ６−ハロプリンの製造方法
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
JP2005538134A (ja) 2002-08-08 2005-12-15 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４阻害剤
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
AU2003267145A1 (en) 2002-09-13 2004-04-30 Irm, Llc Highly specific modulators of gtpases for target validation
AU2003263644A1 (en) 2002-09-26 2004-04-19 Lg Life Sciences Ltd. (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl) methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof
US7601694B2 (en) 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
WO2005012324A2 (en) 2003-07-30 2005-02-10 Gilead Sciences, Inc. Nucleobase phosphonate analogs for antiviral treatment
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
BRPI0413861A (pt) * 2003-08-29 2006-10-24 Vernalis Cambridge Ltd compostos de pirimidotiofeno
US7129244B2 (en) 2003-09-18 2006-10-31 Conforma Therapeutics Corporation Triazolopyrimidines and related analogs as HSP90-inhibitors
ATE500254T1 (de) 2003-09-25 2011-03-15 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
KR20050062940A (ko) 2003-12-19 2005-06-28 주식회사 엘지생명과학 디이소프로필((1-((2-아미노-6-할로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법
KR20050062944A (ko) 2003-12-19 2005-06-28 주식회사 엘지생명과학 디이소프로필((1-((2-아미노-6-클로로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법
WO2005067901A2 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
AR048021A1 (es) 2004-02-17 2006-03-22 Anadys Pharmaceuticals Inc Derivados nucleosido fosfonato utiles en el tratamiento de infecciones de hiv.
JPWO2005092892A1 (ja) 2004-03-26 2008-02-14 大日本住友製薬株式会社 ８−オキソアデニン化合物
BRPI0609509A2 (pt) 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável

Also Published As

Publication number Publication date
US20060223797A1 (en) 2006-10-05
US7544672B2 (en) 2009-06-09
ZA200708520B (en) 2008-10-29
MX2007011903A (es) 2007-12-05
BRPI0609509A2 (pt) 2010-04-13
US20090318387A1 (en) 2009-12-24
IL186270A (en) 2012-08-30
WO2006105372A3 (en) 2007-07-19
EP1869027A2 (en) 2007-12-26
JP2008534609A (ja) 2008-08-28
CN101180297A (zh) 2008-05-14
IL186270A0 (en) 2008-01-20
EA013522B1 (ru) 2010-06-30
NZ561939A (en) 2011-03-31
KR20080004550A (ko) 2008-01-09
CA2602257A1 (en) 2006-10-05
WO2006105372A2 (en) 2006-10-05
US8093229B2 (en) 2012-01-10
NO20075099L (no) 2007-10-29
EA200702109A1 (ru) 2008-06-30
EP1869027A4 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
US8093229B2 (en) Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
US7129244B2 (en) Triazolopyrimidines and related analogs as HSP90-inhibitors
AU2020223731B2 (en) JAK2 and ALK2 inhibitors and methods for their use
AU2003217393B8 (en) Ansamycins having improved pharmacological and biological properties
US20080096903A1 (en) Sulfamoyl-containing derivatives and uses thereof
RU2468026C2 (ru) Производные пуринила и их применение в качестве модуляторов калиевых каналов
US20070253896A1 (en) 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors
JP6803235B2 (ja) タンパク質脱アセチル化酵素阻害剤およびタンパク質脱アセチル化酵素−タンパク質キナーゼ二重阻害剤としての複素環式ヒドロキサム酸ならびにその使用方法
EA011815B1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
US7019002B2 (en) Pyridopyrimidinones derivatives as telomerase inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application